ACM
AXSM icon

Altium Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Altium Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$1.92M – 138
2022
Q2 		$1.92M Buy
+50,000
New +$1.58M 0.77% 55

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Altium Capital Management's AXSM Position: Q4 2024 in Review

Altium Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2024, closing a stake of 58,000 shares — an estimated $5.21M sold.

Altium Capital Management first reported a position in AXSM in Q2 2023 and held it in 6 quarters. The position peaked at $11M in Q1 2024. 292 funds tracked by Wall St. Rank hold AXSM as of Q4 2024.

  • Altium Capital Management reported no remaining Axsome Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Altium Capital Management sold 58,000 Axsome Therapeutics shares in Q4 2024, an estimated $5.21M.
  • Altium Capital Management first reported a position in Axsome Therapeutics in Q2 2023 and held it in 6 quarters.
  • Altium Capital Management's Axsome Therapeutics position peaked at $11M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.